Interaction of opioid growth factor (OGF) and opioid antagonist and their significance in cancer therapy

Int Immunopharmacol
09 August 2019
https://pubmed.ncbi.nlm.nih.gov/31404891/

Low Doses Naltrexone: The Potential Benefit Effects for its Use in Patients with Cancer

Curr Drug Res Rev
26 Jan 2021
https://pubmed.ncbi.nlm.nih.gov/33504322/

The LDN Book Volume 2 & The Goals of the LDN Research Trust (LDN, low-dose Naltrexone) from LDN Research Trust on Vimeo.

LDN Radio Show Dr Neil Paulvin, Dec 2020 (Low dose naltrexone) from LDN Research Trust on Vimeo.

LDN and Cancer Documentary with Italian subtitles (Low dose naltrexone) from LDN Research Trust on Vimeo.

Naltrexone's Impact on Cancer Progression and Mortality: A Systematic Review of Studies in Humans, Animal Models, and Cell Cultures

Adv Ther
18 December 2020
https://pubmed.ncbi.nlm.nih.gov/33337537/

Duration of opioid receptor blockade determines biotherapeutic response

J Clin Gastroenterol
October 2015
https://pubmed.ncbi.nlm.nih.gov/26119823/

Low-Dose Naltrexone in newly diagnosed high-grade glioma: placebo-controlled, double-blind, randomized pilot study

Neuro Oncol
November 2015
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4639177/

Naltrexone at low doses upregulates a unique gene expression not seen with normal doses: Implications for its use in cancer therapy

Int J Oncol
August 2016
https://www.ncbi.nlm.nih.gov/pubmed/27279602

Could Low-Dose Naltrexone be an Effective Treatment for Hailey-Hailey Disease?

Integ Biomed Sci
19 July 2016
https://www.gratisoa.org/journals/index.php/MML/article/view/1293/957